/
PHVS
$34.71+$0.70 (+2.06%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.4B
70M shares
52-week range
$16.72 – $35.33
97% from low
Exchange
NASDAQ
CS
Borrow rate
0.81%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$16.08
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $614 | $8.4K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | −$614 | −$8.4K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.6M | $6.4M | $22.2M | $35.8M | $57.4M | $65.6M | $98.6M | $124.5M |
| Operating income | −$4.3M | −$9.0M | −$28.5M | −$54.1M | −$86.7M | −$96.9M | −$145.7M | −$169.8M |
| EBITDA | −$4.3M | −$9.0M | −$29.7M | −$42.3M | −$86.6M | −$99.6M | −$145.6M | −$173.3M |
| Net income | −$4.3M | −$9.0M | −$29.6M | −$42.7M | −$76.3M | −$100.9M | −$134.2M | −$175.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.14 | -0.25 | -0.85 | -1.41 | -2.27 | -2.63 | -2.48 | -2.97 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-2.58 | $-3.83–$-1.74 | 9 |
| 2027 | $40M | $-2.31 | $-2.92–$-1.44 | 9 |
| 2028 | $155M | $-0.94 | $-2.64–$-0.02 | 5 |
| 2029 | $0 | $1.21 | $-0.25–$3.60 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5.59
Price
$34.71
Implied downside
-84%
Peer comparison
Pharvaris N.V. Ordinary Shares
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
www.pharvaris.com- Employees
- 129
- IPO / List date
- Feb 5, 2021
Held by traders on TradeandTell
No one on the platform currently holds PHVS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PHVS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PHVS yet.
